The 21 billion euro valuation of Mistral AI, while impressive, cannot be presented as the sole informational context for assessing the AI Act's overall viability in a public debate. We need a clear governance process for how such specific market successes translate into broad regulatory assessments, otherwise, it's just anecdotal evidence. Without proper documentation on the methodology for deriving a verdict from this single data point, the debate risks being skewed; imagine trying to approve a new medicine based on one healthy patient without extensive clinical trials and diverse patient data.